These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 32167678)

  • 21. Baculovirus Display of Varicella-Zoster Virus Glycoprotein E Induces Robust Humoral and Cellular Immune Responses in Mice.
    Xue W; Li T; Zhang S; Wang Y; Hong M; Cui L; Wang H; Zhang Y; Chen T; Zhu R; Chen Z; Zhou L; Zhang R; Cheng T; Zheng Q; Zhang J; Gu Y; Xia N; Li S
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.
    Cunningham AL; Heineman TC; Lal H; Godeaux O; Chlibek R; Hwang SJ; McElhaney JE; Vesikari T; Andrews C; Choi WS; Esen M; Ikematsu H; Choma MK; Pauksens K; Ravault S; Salaun B; Schwarz TF; Smetana J; Abeele CV; Van den Steen P; Vastiau I; Weckx LY; Levin MJ;
    J Infect Dis; 2018 May; 217(11):1750-1760. PubMed ID: 29529222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.
    Godeaux O; Kovac M; Shu D; Grupping K; Campora L; Douha M; Heineman TC; Lal H
    Hum Vaccin Immunother; 2017 May; 13(5):1051-1058. PubMed ID: 28068212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design.
    Chen T; Sun J; Zhang S; Li T; Liu L; Xue W; Zhou L; Liang S; Yu Z; Zheng Q; Yu H; Cheng T; Zhang J; Gu Y; Li S; Xia N
    Sci China Life Sci; 2023 Apr; 66(4):743-753. PubMed ID: 36790656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence of Varicella-Zoster Virus-Specific Plasma Cells in Adult Human Bone Marrow following Childhood Vaccination.
    Eberhardt CS; Wieland A; Nasti TH; Grifoni A; Wilson E; Schmid DS; Pulendran B; Sette A; Waller EK; Rouphael N; Ahmed R
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32321817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Vaccines against varicella-zoster virus (VZV)].
    Salleras L; Salleras M; Soldevila N; Prat A; Garrido P; Domínguez Á
    Enferm Infecc Microbiol Clin; 2015; 33(6):411-23. PubMed ID: 26096575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Th1 memory differentiates recombinant from live herpes zoster vaccines.
    Levin MJ; Kroehl ME; Johnson MJ; Hammes A; Reinhold D; Lang N; Weinberg A
    J Clin Invest; 2018 Oct; 128(10):4429-4440. PubMed ID: 30024861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine.
    Perciani CT; Jaoko W; Walmsley S; Farah B; Mahmud SM; Ostrowski M; Anzala O; Team KI; MacDonald KS
    BMJ Open; 2017 Sep; 7(9):e017391. PubMed ID: 28939581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Synergistic Lipid Nanoparticle Encapsulating mRNA Shingles Vaccine Induces Potent Immune Responses and Protects Guinea Pigs from Viral Challenges.
    Cheng X; Liu S; Sun J; Liu L; Ma X; Li J; Fan B; Yang C; Zhao Y; Liu S; Wen Y; Li W; Sun S; Mi S; Huo H; Miao L; Pan H; Cui X; Lin J; Lu X
    Adv Mater; 2024 Mar; 36(13):e2310886. PubMed ID: 38145557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study.
    Chlibek R; Smetana J; Pauksens K; Rombo L; Van den Hoek JA; Richardus JH; Plassmann G; Schwarz TF; Ledent E; Heineman TC
    Vaccine; 2014 Mar; 32(15):1745-53. PubMed ID: 24508036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.
    Weinberg A; Pang L; Johnson MJ; Caldas Y; Cho A; Tovar-Salazar A; Canniff J; Schmader KE; Popmihajlov Z; Levin MJ
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.
    Berkowitz EM; Moyle G; Stellbrink HJ; Schürmann D; Kegg S; Stoll M; El Idrissi M; Oostvogels L; Heineman TC;
    J Infect Dis; 2015 Apr; 211(8):1279-87. PubMed ID: 25371534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune responses to zoster vaccines.
    Levin MJ; Weinberg A
    Hum Vaccin Immunother; 2019; 15(4):772-777. PubMed ID: 30676834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine.
    Heineman TC; Cunningham A; Levin M
    Curr Opin Immunol; 2019 Aug; 59():42-48. PubMed ID: 31003070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.
    Diez-Domingo J; Weinke T; Garcia de Lomas J; Meyer CU; Bertrand I; Eymin C; Thomas S; Sadorge C
    Vaccine; 2015 Feb; 33(6):789-95. PubMed ID: 25555381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant Glycoprotein E of Varicella Zoster Virus Contains Glycan-Peptide Motifs That Modulate B Cell Epitopes into Discrete Immunological Signatures.
    Nordén R; Nilsson J; Samuelsson E; Risinger C; Sihlbom C; Blixt O; Larson G; Olofsson S; Bergström T
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30813247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Recombinant Herpes Zoster Vaccine for Primary Immunization of Varicella-seronegative Transplant Recipients.
    L'Huillier AG; Hirzel C; Ferreira VH; Ierullo M; Ku T; Selzner N; Schiff J; Juvet S; Miao C; Schmid DS; Humar A; Kumar D
    Transplantation; 2021 Oct; 105(10):2316-2323. PubMed ID: 33528118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus.
    Laing KJ; Russell RM; Dong L; Schmid DS; Stern M; Magaret A; Haas JG; Johnston C; Wald A; Koelle DM
    J Infect Dis; 2015 Oct; 212(7):1022-31. PubMed ID: 25784732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization.
    Haumont M; Jurdan M; Kangro H; Jacquet A; Massaer M; Deleersnyder V; Garcia L; Bosseloir A; Bruck C; Bollen A; Jacobs P
    J Med Virol; 1997 Sep; 53(1):63-8. PubMed ID: 9298734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.
    Weinberg A; Canniff J; Rouphael N; Mehta A; Mulligan M; Whitaker JA; Levin MJ
    J Immunol; 2017 Jul; 199(2):604-612. PubMed ID: 28607114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.